Tevard's tRNA Therapy Restores 70% Protein in Muscular Dystrophy

Tevard Biosciences, a pioneering biotechnology company, has unveiled groundbreaking preclinical data demonstrating the remarkable efficacy of its suppressor tRNA platform in treating devastating genetic disorders. During the prestigious 2025 Federation of European Biochemical Societies Special Meeting in Dubrovnik, Croatia, Chief Scientific Officer Dr. Elisabeth Gardiner presented compelling evidence showing that the company's engineered suppressor tRNAs can restore approximately 70% of full-length wild-type dystrophin protein in Duchenne muscular dystrophy models. The platform also demonstrated significant success in treating dilated cardiomyopathy caused by titin truncations, marking the first public disclosure of results from Tevard's DCM-TTNtv program and underscoring the versatility of their innovative approach across genetically distinct conditions.

The key findings revealed that AAV-delivered suppressor tRNAs targeting specific nonsense mutations produced dramatic results in both disease models. In DMD, the treatment not only restored high levels of functional dystrophin but also correlated with motor function recovery and normalization of proteomic biomarkers. For DCM-TTNtv, the therapy restored full-length titin protein expression and contractility in human cardiomyocytes within just four days, with in vivo studies showing robust protein production and restored proteomic homeostasis within six weeks. Both programs demonstrated dose-dependent improvements following systemic administration, with no detectable toxicity or off-target effects, and the therapeutic benefits remained sustained for up to 12 weeks post-treatment following a single intravenous dose.

Under the leadership of Co-Founder, President and CEO Daniel Fischer, Tevard's platform has evolved from first-generation molecules to sophisticated third-generation candidates optimized through high-throughput screening of over 80,000 variants. These rationally engineered suppressor tRNAs efficiently read through the most common premature stop codons that underlie 10-40% of all genetic diseases. The company's innovative approach uses native cellular machinery to produce natural proteins that function as the body intended, representing a significant advancement in genetic medicine. Both the DMD and DCM programs are advancing toward development candidate nomination in early 2026, with interested parties encouraged to visit www.tevard.com for more information about this transformative biotechnology platform.